Denali Therapeutics Inc. (DNLI)
Automate Your Wheel Strategy on DNLI
With Tiblio's Option Bot, you can configure your own wheel strategy including DNLI - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol DNLI
- Rev/Share 0.0
- Book/Share 5.9904
- PB 2.8245
- Debt/Equity 0.0453
- CurrentRatio 10.2651
- ROIC -0.4923
- MktCap 2473911744.0
- FreeCF/Share -2.1461
- PFCF -6.7235
- PE -6.0558
- Debt/Assets 0.0399
- DivYield 0
- ROE -0.4079
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | DNLI | Cantor Fitzgerald | Neutral | Overweight | -- | -- | April 10, 2025 |
| Resumed | DNLI | Morgan Stanley | -- | Overweight | $41 | $33 | March 7, 2025 |
| Initiation | DNLI | Deutsche Bank | -- | Buy | -- | $31 | Feb. 11, 2025 |
| Initiation | DNLI | Robert W. Baird | -- | Outperform | -- | $31 | Jan. 7, 2025 |
| Initiation | DNLI | William Blair | -- | Outperform | -- | -- | Jan. 3, 2025 |
| Upgrade | DNLI | Stifel | Hold | Buy | -- | $37 | Dec. 16, 2024 |
| Resumed | DNLI | Raymond James | -- | Market Perform | -- | -- | Oct. 10, 2024 |
| Downgrade | DNLI | Cantor Fitzgerald | Overweight | Neutral | -- | -- | Oct. 7, 2024 |
News
FDA Delays Decision Date For Denali Therapeutics' Lead Drug Candidate
Published: October 14, 2025 by: Benzinga
Sentiment: Negative
The U.S. Food and Drug Administration extended on Monday Denali Therapeutics Inc.'s (NASDAQ:DNLI) review timeline of the Biologics License Application (BLA), seeking accelerated approval of tividenofusp alfa for the treatment of mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome.
Read More
FDA Extends Review of DNLI's Hunter Syndrome Drug by Three Months
Published: October 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Denali Therapeutics faces an FDA review delay for its Hunter syndrome drug, pushing potential approval of tividenofusp alfa to April 2026.
Read More
Why Is Denali Therapeutics (DNLI) Up 16.2% Since Last Earnings Report?
Published: September 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock?
Read More
DNLI Tops on Q2 Earnings, Expects Decree on Hunter Syndrome Drug in '26
Published: August 12, 2025 by: Zacks Investment Research
Sentiment: Neutral
Denali Therapeutics posts narrower-than-expected Q2 loss. The company advances multiple rare disease therapies toward potential approvals.
Read More
DNLI's BLA for Hunter Syndrome Drug Gets FDA's Priority Review
Published: July 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Denali's lead drug for Hunter syndrome wins FDA Priority Review, marking a key step toward commercial-stage status.
Read More
Why Is Denali Therapeutics (DNLI) Up 0.7% Since Last Earnings Report?
Published: June 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock?
Read More
Denali Q1 Loss Wider Than Expected, Hunter Syndrome Drug in Focus
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Negative
DNLI reports a wider-than-expected loss for the first quarter of 2025. Denali submits a BLA for tividenofusp alfa under the FDA?
Read More
5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Let us look at some drug/biotech stocks, NVO, PCRX, RARE, ACAD and DNLI, which are poised to beat on first-quarter 2025 earnings.
Read More
DNLI Begins Rolling BLA Submission for Hunter Syndrome Drug, Stock Up
Published: April 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Denali stock up as it begins rolling BLA submission with the FDA for accelerated approval of tividenofusp alfa for the treatment of Hunter syndrome.
Read More
Denali Therapeutics: Vast Pipeline, First Approval Up Ahead
Published: March 20, 2025 by: Seeking Alpha
Sentiment: Positive
Denali Therapeutics' stock has significantly dropped from $100 to $15 since 2021, but the company is now heavily derisked with promising product candidates nearing key milestones. Lead asset DNL310 shows strong biomarker data for Hunter syndrome, with plans for a BLA submission and accelerated approval by Q2 2025. The Biogen partnership for Parkinson's Disease asset DNL151 includes substantial milestone payments and profit-sharing, highlighting its potential impact.
Read More
Why You Shouldn't Bet Against Denali (DNLI) Stock
Published: March 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Denali (DNLI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Read More
Denali Q4 Earnings Beat Estimates, Hunter Syndrome Drug in Focus
Published: February 28, 2025 by: Zacks Investment Research
Sentiment: Neutral
DNLI reports a narrower-than-expected loss for the fourth quarter of 2024. Denali remains on track to submit a BLA for tividenofusp alfa for the treatment of MPS II (Hunter syndrome).
Read More
Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the fourth quarter and year ended December 31, 2024, and provided business highlights.
Read More
About Denali Therapeutics Inc. (DNLI)
- IPO Date 2017-12-08
- Website https://www.denalitherapeutics.com
- Industry Biotechnology
- CEO Ryan J. Watts
- Employees 443